Department of Transplantation Medicine, Oslo University Hospital.
Department of Pharmacy, University of Oslo; and.
Ther Drug Monit. 2020 Jun;42(3):407-414. doi: 10.1097/FTD.0000000000000697.
Therapeutic drug monitoring (TDM) of tacrolimus (Tac) is mandatory in renal transplant recipients (RTxR). Area under the concentration versus time curve (AUC) is the preferred measure for Tac exposure; however, for practical purposes, most centers use trough concentrations as a clinical surrogate. Limited sampling strategies in combination with population pharmacokinetic model-derived Bayesian estimators (popPK-BE) may accurately predict individual AUC. The use of self-collected capillary microsamples could simplify this strategy. This study aimed to investigate the potential of AUC-targeted Tac TDM using capillary microsamples in combination with popPK-BE.
A single-center prospective pharmacokinetic study was conducted in standard-risk RTxR (n = 27) receiving Tac twice daily. Both venous and capillary microsamples (Mitra; Neoteryx, Torrance, CA) were obtained across 2 separate 12-hour Tac dosing intervals (n = 13 samples/AUC). Using popPK-BE, reference AUC (AUCref) was determined for each patient using all venous samples. Different limited sampling strategies were tested for AUC predictions: (1) the empiric sampling scheme; 0, 1, and 3 hours after dose and (2) 3 sampling times determined by the multiple model optimal sampling time function in Pmetrics. Agreement between the predicted AUCs and AUCref were evaluated using C-statistics. Accepted agreement was defined as a total deviation index ≤±15%.
The AUC from capillary microsamples revealed high accuracy and precision compared with venous AUCref, and 85% of the AUCs had an error within ±11.9%. Applying microsamples at 0, 1, and 3 hours after dose predicted venous AUCref with acceptable agreement. Patients performed self-sampling with acceptable accuracy.
Capillary microsampling is patient-centered, making AUC-targeted TDM of Tac feasible without extended hospital stays. Samples obtained 0, 1, and 3 hours after dose, combined with popPK-BE, accurately predict venous Tac AUC.
在肾移植受者(RTxR)中,他克莫司(Tac)的治疗药物监测(TDM)是强制性的。浓度-时间曲线下面积(AUC)是 Tac 暴露的首选测量方法;然而,出于实际目的,大多数中心将谷浓度作为临床替代物。结合群体药代动力学模型衍生的贝叶斯估计器(popPK-BE)的有限采样策略可以准确预测个体 AUC。使用自我采集的毛细血管微样本可以简化该策略。本研究旨在调查使用毛细血管微样本结合 popPK-BE 进行 AUC 靶向 Tac TDM 的潜力。
在接受 Tac 每日两次的标准风险 RTxR(n = 27)中进行了一项单中心前瞻性药代动力学研究。在 2 个单独的 12 小时 Tac 给药间隔(n = 13 个样本/AUC)中采集静脉和毛细血管微样本(Mitra;Neoteryx,托伦斯,加利福尼亚州)。使用 popPK-BE,使用所有静脉样本确定每个患者的参考 AUC(AUCref)。测试了不同的有限采样策略来预测 AUC:(1)经验采样方案;在剂量后 0、1 和 3 小时,以及(2)Pmetrics 中的多模型最佳采样时间函数确定的 3 个采样时间。使用 C 统计量评估预测 AUC 与 AUCref 的一致性。接受的一致性定义为总偏差指数≤±15%。
与静脉 AUCref 相比,毛细血管微样本的 AUC 具有很高的准确性和精密度,85%的 AUC 误差在±11.9%以内。在剂量后 0、1 和 3 小时应用微样本可以接受地预测静脉 AUCref。患者能够准确地进行自我采样。
毛细血管微采样以患者为中心,无需延长住院时间即可实现 Tac 的 AUC 靶向 TDM。在剂量后 0、1 和 3 小时采集的样本,结合 popPK-BE,可准确预测静脉 Tac AUC。